Abstract
Background: The Multicenter Selective Lymphadenectomy Trial II (MSLT-II) demonstrated that complete lymph node dissection (CLND) following positive SLNB is not associated with improved melanoma-specific survival when compared with close clinical follow-up and ultrasound of the affected nodal basin.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
